Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 5

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 5
---
     |          |     |  -77.2 |     | -30.1 | % |     |     | -28.1 | %                         |
| Income tax expenses                                                              |     |            |     |   -68.6 |     |           |     |   -66.3 |     |          |     |    2.3 |     |  -3.4 | % |     |     |  -6.9 | %                         |
| Net profit for the period                                                        |     |            |     |   187.4 |     |           |     |   112.5 |     |          |     |  -74.9 |     | -39.9 | % |     |     | -35.8 | %                         |
| Net profit for the period attributable to owners of the Company                  |     |            |     |   187.3 |     |           |     |   112.4 |     |          |     |  -74.9 |     | -40.0 | % |     |     | -35.9 | %                         |

In this section, the amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. For additional information on CER change, see “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

#### Revenue
Revenue for the six-month period ended September 30, 2025 was JPY 2,219.5 billion (JPY -164.5 billion and -6.9% AER, -3.9% CER). The decline compared to the same period of the previous fiscal year was primarily attributable to a decrease in revenue in Neuroscience, one of our six key business areas and unfavorable foreign exchange rates. The decrease in Neuroscience was largely attributable to the continued impact from generic erosion of VYVANSE (for attention deficit hyperactivity disorder (“ADHD”)) in the U.S. Excluding foreign exchange rates impact, revenue slightly increased in our key business areas of Gastroenterology (“GI”), Rare Diseases, Plasma-Derived Therapies (“PDT”), and Oncology, while there was a decline in Vaccines. While certain products faced headwinds due to the impact